Adam M. Koppel joined Bain Capital Public Equity in 2003, where he was a leader within the healthcare sector until 2014. From 2014 to 2016, he was EVP of Corporate Development and Chief Strategy Officer at Biogen. Prior to joining Bain Capital Public Equity in 2003, Dr. Koppel was an associate principal at McKinsey & Co in New Jersey where he served a variety of healthcare companies.
Dr. Koppel sits on the Board of Directors of Areteia Therapeutics, Cardurion Pharmaceuticals and Foghorn Therapeutics. Previously served on the Board of Aptinyx, Cerevel Therapeutics, Dicerna Pharmaceuticals), PTC Therapeutics, Solid Biosciences, Trevena, Inc and ViaCyte Inc.
Dr. Koppel serves on the Board of Trustees at the Boston Museum of Science, Newton-Wellesley Hospital and CJP Boston. He sits on the Investment Committees of the Boston Museum of Science and the Society for Neuroscience and is on the Mass General Brigham Innovation Growth Board.
Dr. Koppel received an MD and PhD in Neuroscience from the University of Pennsylvania School of Medicine, and an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Harvard University with an AB and AM in History and Science.

Allen is the former co-founder and managing partner of OurCrowd Qure, Israel’s first exclusively focused digital health fund. Prior to this venture, Allen co-founded Humedica, which was sold in 2013 to UnitedHealth (NYSE: UNH – the largest US health insurer). Allen previously served as the Chief Commercial Officer of Optum Analytics, Director at healthcare investment bank, Leerink Swann, and as Director of Decision Support at Biogen. With nearly 25 years of healthcare experience, Allen began his career as a reporter for The Pink Sheet, covering pharmaceutical industry issues at the FDA and Capitol Hill.

Alise is the President and CEO of Tectonic Therapeutic, focusing on biologics for challenging GPCR targets. With 20+ years in R&D, she previously served as President of Global Clinical Development at Celgene. Her career spans Merck, EMD Serono, and Celgene, where she led teams that supported the approval of 15+ novel drugs, generating over $30B in global sales across autoimmune
and oncology. Notably, at Merck, she led the team that brought Keytruda®
from Phase I through initial approvals and Phase II/III studies. Alise holds an M.D. with honors from Harvard Medical School and a B.A. from Barnard
College. She has also served as a faculty member at Columbia University’s
Medical School, specializing in infectious disease research. Alise currently sits on the Boards of Sana Biotechnology, Immatics, and Sharsheret.

Amir Dan Rubin has focused his career on helping transform health care. He currently serves as CEO & Founding Managing Partner of Healthier Capital, a venture capital firm focused on technology-powered healthcare innovation. He previously served as Chair & CEO of the technology-enabled primary care company, One Medical, which he took public in 2020 and which was acquired by Amazon in 2023. At Amazon, he launched One Medical membership as an add-on to Prime. Before that, Amir served as an EVP at the Fortune 5 company, UnitedHealth Group and its Optum division. Prior to that, he served as CEO at Stanford University’s health system, COO at UCLA’s health system, COO at SUNY Stony Brook’s health system, and in leadership roles at Memorial Hermann’s health system. He has twice received an EY “Entrepreneur of the Year” award.

Dr. Anat Cohen-Dayag has over 25 years of experience in the biotech industry, both in R&D and executive leadership roles. Anat joined Compugen in 2002, and has held various senior managerial positions, including VP R&D, before being appointed President and CEO in 2010. Under her leadership, Compugen transformed from a service provider in the field of computational biology to a therapeutic discovery and development company advancing an innovative immuno-oncology pipeline, originating from the company’s computational discovery platforms. Anat joined Compugen’s Board of Directors in 2014 and is also a member of the Board of Directors of Pyxis Ltd. and Genopore Ltd. Prior to Compugen, Anat was the Head of R&D and a member of the executive management team of Mindsense Biosystems Ltd. Anat holds a B.Sc. in Biology from Ben-Gurion University, an M.Sc. in Chemical Immunology and a Ph.D. in Cellular Biology, both from the Weizmann Institute of Science.

Drew Fromkin is the Chief Executive Officer of Pulmovant and has served as Vant Portfolio Operating Partner for Roivant Sciences, Inc. (ROIV) since January 2021. He currently serves on the Board of Immunovant (IMVT) as Chair of the Compensation and Nominating and Governance committees and previously served as the Chief Executive Officer of Proteovant Therapeutics.
Mr. Fromkin is a highly accomplished global healthcare leader who over his 35-year career has led and served on the boards of public and private healthcare companies. Most notably, Mr. Fromkin served as President, Chief Executive Officer, and Director of Clinical Data, Inc. from 2006-2011. CLDA was sold to Forest Labs for a total consideration of $1.5 Billion. Mr. Fromkin has also served as Chairman and CEO of Tarveda Therapeutics, President and Chief Executive Officer of DoctorQuality, Inc. (sold to Quantros, Inc.), President, Chief Executive Officer and Director of Endo Surgical Devices, Inc. and Corporate Vice President, Business Development, for Merck-Medco, a wholly-owned subsidiary of Merck & Co. (MRK). From 2014 until 2016, Mr. Fromkin also served on the board of Regado Biosciences, Inc. which became Tobira Therapeutics, Inc. in 2015 (sold to Allergan for $1.7 Billion). Mr. Fromkin earned his B.A. in biology from Brandeis University.

Avi Veidman is a Tech-Bio leader with over 25 years of experience directing multidisciplinary teams in complex, unpredictable environments. As the CEO of Nucleai, he spearheads the development of an innovative spatial biology platform that leverages AI Pathology to find the best treatments for cancer patients and transform drug research, development, and clinical decision-making. Under his leadership, Nucleai has raised more than $60 million from top-tier investors, including Section 32, Sanofi and Merck.
Before founding Nucleai, Avi spent two decades in IDF's elite intelligence units, pioneering AI and data science initiatives focusing on computer vision and spatial information analysis. He holds a Master’s and Bachelor’s degree in Geoinformatics from the Technion, graduating cum laude.
Avi is an active member of 8400 The Health Network, where he mentors CEOs and initiates various impact programs.
Before founding Nucleai, Avi spent two decades in Israel's elite intelligence units, pioneering AI and data science initiatives with a focus on computer vision and spatial information analysis. He holds a Master’s and Bachelor’s degree in Geoinformatics from the Technion, graduating cum laude.
Avi is an active member of the 8400 - The Health Network, where he mentors CEOs and initiates various programs.

Avner Halperin is an entrepreneur, executive and researcher in the fields of medical technology, policy and AI Economics. He is the CEO of Sheba Impact – the Medical Center’s commercialization company, where he built a startup ecosystem worth billions of dollars. He is also a Research Fellow at Harvard Kennedy School, as well as Chairman of the Board at EyeControl (winner of the Genesis Award for contribution to the battle against COVID-19). He is a faculty of Tel Aviv University, teaching AI & Big Data Economics, and the Hebrew University of Jerusalem, teaching economics and entrepreneurship.
Previously, he was the founding CEO of EarlySense for 15 years - bringing the company from the idea stage to serving over 10 million patients and assisting in saving tens of thousands of lives.
Avner earned an MSc in Applied Physics from Tel Aviv University and an MBA from MIT, where he researched globally dispersed teams. He invented 34 US Patents and gave a TED talk on Artificial Intelligence in Healthcare in 2019.
Previously, he was the founding CEO of EarlySense for 15 years - bringing the company from the idea stage to serving over ten million patients and assisting in saving tens of thousands of lives.
Avner earned an MSc in Applied Physics from Tel Aviv University and an MBA from MIT, where he researched globally dispersed teams. He also taught courses on economics and entrepreneurship in the Hebrew University of Jerusalem. He invented 34 US Patents, and gave a TED talk on Artificial Intelligence in Healthcare in 2019.

Boris Kheyn is the Life Sciences Health Care Platforms and Ecosystems Leader at Deloitte. He has over 12 years of experience in growth strategy, advising the largest plans, providers, health technology, and life sciences companies. Boris works with national health plans, major health systems, life science companies, and consumer tech companies to launch new health products and businesses. He architects partnerships between leading health tech companies and health organizations to access new capabilities and enter new markets.
Boris has lectured on and contributed to numerous articles on the healthcare industry relating to platforms, innovation, and ecosystems. Boris holds an MBA from Columbia University and a BA in Economics from UCLA.

David has spent the past 25 years working to assist clients’ life science innovation strategies. This work has included a range of portfolio, drug development, investment, transactional and partnering strategies. While the therapeutic span of David’s work has crossed a broad swath of medicine, particular areas of focus have included: oncology, immunology, infectious disease as well as rare and orphan segments.
Prior to joining ClearView, David spent the majority of his career as a Managing Director of The Frankel Group in NYC and Israel ultimately serving as Managing Director and lead of Huron’s Life Science Strategy team. Most recently, David served as Global Head-Portfolio Management, Business Development & Licensing, at Novartis Oncology as well as CBO of ADC Therapeutics. In addition to client work, David has spent time teaching life sciences to business students and business to medical students and has published across drug pricing and reimbursement as well as innovation ecosystem economics.
David holds a A.B., with honors, in East Asian History from the University of Chicago and an MBA from the University of Texas at Austin.

Dr. David Israeli is the Chairman & CEO of Magenta Medical, a start-up company developing a temporary mechanical circulatory support device for acute indications. Prior to that, David was the Chief Medical Officer of Ossio Ltd., a start-up company developing novel implants for orthopedic fixation.
Previously, he was a life sciences General Partner at Pitango Venture Capital, one of the leading VCs in Israel, where he led investments in the areas of medical devices and digital health.
Before joining Pitango, David was the Director of Business Development and Marketing at Medtronic Ventor Technologies, following Medtronic’s acquisition of Ventor Technologies in 2009.
Prior to that, David spent several years in the United States. At Medtronic he led corporate development and M&A to business and market development. David then went on to become the VP of Medical Affairs at Rhythmia Medical, which was acquired by Boston Scientific in 2012.
David holds an MD from the Hebrew University of Jerusalem and an MBA from the Harvard Business School.

Deborah Estrin is the Tishman Professor of Computer Science, Associate Dean for Impact, and founder of the Public Interest Technology Initiative (PiTech) at Cornell Tech. Current research activities focus on Digitally Enabled Care. Earlier research included distributed and participatory sensing, mobile technologies, and Internet protocols. Honors: American Academy of Arts and Sciences, National Academy of Engineering, National Academy of Medicine, and MacArthur Fellow.

Gal Markel, MD, PhD, MBA is the Director of Davidoff Comprehensive Cancer Center at Rabin Medical Center, Deputy Director General of Rabin Medical Center and Founder & Chairman of the Samueli Cancer Pioneering Institute.
He is a Full Professor of Immunology & Oncology at Tel-Aviv University.
Previously served for 16 years as an Investigator, chief scientist, senior oncologist and director at Sheba Hospital's Institute for Immuno-Oncology.
He is the Founder of 5 companies, of which 2 were acquired by corporations (MSD- $95M, DSPG- $10M)
He serves as Scientific Advisory Board member on multiple national-level and international companies. He received multiple national & international awards for outstanding research and is an invited speaker on multiple international scientific & popular platforms such as AACR, TED MED, etc.
He is a member of multiple national committees regarding oncology, cancer research and academic medicine.

Gilad Glick is the Vice President, Venture Investments – Pharma Israel and MedTech Israel and Europe at Johnson & Johnson. His work includes engaging with entrepreneurs, startups, incubators, and accelerators, particularly focusing on Israel and the MedTech Group in Europe.
Prior to that, Gilad served as the CEO of Itamar Medical, a publicly traded sleep apnea diagnostic and digital care pathway company, where he led the company for over eight years until its acquisition by ZOLL Medical. Before that, Gilad spent over 17 years at Johnson & Johnson, holding various roles in medical devices across Europe and the US. His experience spans sales, marketing, service, and R&D. In his last role with J&J, he served as Vice President, Global Sales and Marketing for Biosense Webster, overseeing strategic and commercial operations for a business with $1.5 billion in revenue.
Gilad earned his MBA from the Maastricht School of Management in the Netherlands, majoring in general and strategic management. He is also a graduate of Stanford Graduate School of Business’s prestigious Strategic Marketing Management Executive Program. Additionally, Gilad is a member of the 8400 Health Network, founder of the MedTech Commercialization Institute, and serves on the Board of Directors for Beta Bionics.

Gary Gottlieb is a professor of psychiatry at Harvard Medical School and a member of
the National Academy of Medicine. From 2015-2019, he served as CEO of Partners In
Health, a global NGO providing a preferential option for the poor in health care in
severely resource constrained settings. He assumed this role after serving on the PIH
Board of Directors for a decade. From 2010 until February of 2015, Dr. Gottlieb was the
CEO of Partners HealthCare (now MassGeneral Brigham), the parent of the Brigham
and Women’s and Massachusetts General Hospitals, the largest health care delivery
organization in New England and among the largest biomedical research and training
enterprises in the US. From 2002-2009, he was President of Brigham and Women’s
Hospital. Previously, he served as President of North Shore Medical Center and as
Chair of Partners Psychiatry and Mental Health System. Dr. Gottlieb served as a
member of the Board of Directors of the Federal Reserve Bank of Boston from 2012-
2016 and as its chair from 2016-2018. From 2006-2016, he was Chair of the Boston
Private Industry Council, the workforce board of the City of Boston. Prior to coming to
Boston, Dr. Gottlieb spent 15 years in positions of increasing leadership in health care in
Philadelphia. He established the University of Pennsylvania Medical Center’s first
program in geriatric psychiatry and developed it into a nationally recognized research,
training, and clinical program. He served as executive vice-chair of psychiatry and
associate dean for managed care at the University of Pennsylvania Medical Center, and
as director and CEO of Friends Hospital, the nation’s first freestanding psychiatric
hospital. Dr. Gottlieb is currently an Executive Partner at Flare Capital Partners, a
Boston venture firm investing in early stage health related technology companies. He is
Executive Chair of the boards of Cohere Health and Author Health and he is a director
at OM1, Kyruus and IMO. Dr. Gottlieb received a B.Sc. cum laude from Rensselaer
Polytechnic Institute and an M.D. from Albany Medical College in a six-year accelerated
program and he completed a psychiatry residency at New York University/Bellevue
Medical Center. As a Robert Wood Johnson Clinical Scholar at Penn, he earned an
M.B.A. with distinction from the Wharton School of Business at the University of
Pennsylvania.

Dr. Gad Getz is an internationally acclaimed leader in cancer genomics and is pioneering widely-used tools for analyzing cancer genomes. Dr. Getz is a Professor of Pathology at Harvard Medical School. He is the Director of Bioinformatics at the Massachusetts General Hospital (MGH) Cancer Center and Department of Pathology and is an Institute Member of the Broad Institute of MIT and Harvard, where he directs the Cancer Genome Computational Analysis Group. He has published over 500 papers in prominent journals describing new methodologies to study cancer genomes that have identified new genes and pathways involved in different tumor types, mutational signatures, and tumor evolution.

Hadas serves as the Health Cluster Manager, where she leads the process of mapping Israel’s health innovation ecosystem through a dynamic digital platform. She is responsible for strengthening the cluster at all levels, developing tools to foster cross-sector collaboration and investment, and promoting Israeli health companies in global markets.
Previously, Hadas was Head of Organizational Innovation at HealthIL, a leading innovation community in Israel’s healthcare sector. In this role, she expanded HealthIL’s outreach, supported health organizations in building innovative infrastructures, and cultivated a strong culture of innovation. She also led the development of practical tools for implementing innovation within healthcare settings.
Prior to entering the civilian sector, Hadas served as a Lieutenant Colonel in the IDF, where she led the Organizational Development Branch at the Technology & Logistics Directorate. She advised senior commanders on strategic planning, managed complex change initiatives, and established internal innovation frameworks.
Hadas holds an M.A. in Psychology from Ben-GurionUniversity and is a certified expert in Occupational Psychology.

Hagai served for 34 years in elite defense agencies in managerial positions, most recently as director of the technological directorate at the PMO. He established and managed the national COVID-19 nerve center at Sheba Hospital. Hagai is currently Director of Industry Relationships at TAU, Chairman of RAMOT & TAU Ventures, Partner & CTO of i-Next capital, A consultant and board member in tech companies, and Chairman of a non-profit organization.
He holds a BA in economics from the Hebrew University of Jerusalem and an MBA from Ben-Gurion University.

Issi Rozen is a general partner at GV, where he primarily focuses on the formation of new companies and early-stage investments. Issi is an experienced biotech executive and a serial entrepreneur who co-founded multiple startups. Prior to joining GV Issi served as the Chief Business Officer and a member of the executive leadership team at the Broad Institute of MIT and Harvard, where he led the creation of the Office of Strategic Alliances and Partnering. He was responsible for developing innovative scientific and business collaborations, initiating and establishing new ventures around novel technologies, and overseeing strategy and licensing of the Institute’s intellectual property portfolio.

Ittai Harel is a Managing Partner with Pitango Venture Capital, and leads the activity of Pitango HealthTech Fund. His experience includes 25 years of entrepreneurship and executive roles in general management, business development, and marketing with life-science technology companies ranging from digital health, biopharma and medical devices to diagnostics and veterinary health.

Kfir Battat is a civil servant and economist currently serving as the Deputy Director in the Ministry of Finance's Budget Department. In this role, he oversees a team responsible for budget appropriation and economic policy across various fields, including the labor market, the HiTech sector, higher education, agriculture and more. Kfir holds a Master’s degree in Financial Economics from the Hebrew University of Jerusalem and a Master’s degree in Public Administration from the Harvard Kennedy School. Outside of work, he is happily married to Reut and is a proud father of three young children; Yuval, Yarden and Rotem

For two decades Laizer Kornwasser has led business transformation and been at the forefront of high growth health care companies. His track record of success encompasses diverse experiences ranging from PBM/Pharma service, Pharma, Health Care Services, Health Care Technology, B2B sales to Health Plans and Employers and Direct to Consumer. Kornwasser held executive leadership roles at health care companies including Teladoc, Carecentrix and Medco Health Solutions.
Mr. Kornwasser earned a Master of Business Administration from Harvard Business School and a Bachelor of Science from Yeshiva University where he is a professor.

Lee Shapiro is Partner at 7wire Ventures, an investment firm he co-founded over a decade ago. He also served as a Board Member and Chief Financial Officer of Livongo Health until November 2020. Previously he was President of Allscripts from 2001 until the end of 2012.
Lee served on the board of Senior Connect, a special purpose acquisition company, and the board of directors of Medidata Solutions until its sale in 2019 to Dassault Systemes. He also served on the board of Tivity Health until May 2020. In January, 2021, Lee joined the board of Click Therapeutics. He also serves on the boards and committees of various 7wire Ventures portfolio companies.
Lee serves on the National Board of Directors of the American Heart Association as Chair Elect, assuming his new role in July 2025.

Mati Gill is CEO of AION Labs, a venture studio with a first-of-its-kind company creation model for new start-ups utilizing AI for drug discovery and development. Supported by the Israeli Government, AION Labs was formed from the unique alliance of Pfizer, Amazon Web Services, AstraZeneca, Teva Pharmaceuticals, Merck, the Israel Biotech Fund, Amiti Ventures and BioMed X. Prior to founding AION Labs, Mati was a senior executive at Teva Pharmaceuticals and served as Chief of Staff for Israel’s Minister of Public Security. He is an IDF veteran (Maj. res.) serves on the boards of the Israel Advanced Technology Industries Association (IATI) and the Israel America Chamber of Commerce (AmCham).

Michal Fink is Deputy Director General and head of Strategy, Economics and Innovation Directorate at the Ministry of Economy and Industry. Michal initiated this new organizational division to boost Israeli economy's growth, primarily through developing competitive clusters and innovation communities, while creating a competitive ecosystem to encourage growth in advanced sectors.
Previously, Michal served as head of Strategy and Policy Planning and initiated the government's first Policy Division. She initiated policy measures and significantly contributed to developing new directions and tools for fulfilling the Ministry of Economy's role, including programs for regional economic development and promotion of the periphery, strengthening industry and encouraging productivity, expanding the concept of innovation, promoting trade and services sectors, and more. Before that, she served as Director of the Operation and Methods Unit in the ministry, as an economist and project manager at the Investment Center, and as Acting Head of the Economic and Social Development Division for Bedouins in the Negev.
Michal holds an MBA from the Hebrew University in Jerusalem, completed executive training programs at Harvard University's Schools of Public Policy and Business, and is a graduate of the Wexner Foundation and Maoz Organization's senior executive leadership programs.

Michal Preminger currently serves as the Regional Head for Johnson & Johnson Innovation, East North America, where she leads the team responsible for early-stage incubation, investments, collaborations, and licensing of transformational assets and enabling technologies to feed the pipelines of Johnson & Johnson’s Innovative Medicines and Med Tech businesses on behalf of patients.
Previously, Michal held senior leadership roles at Harvard University, overseeing technology development and strategic partnerships at Harvard Medical School.
Earlier in her career, Michal held key executive roles at Compugen, where she contributed to the development of genomics, proteomics and predictive medicine technologies, and in the hi-tech industry. She served on multiple boards and scientific advisory boards including Israeli organizations Elminda, Alma Lasers, FutuRx, Prize4Life and Core Dynamics.
Michal is currently a highly engaged Board member of MassBio, the Kendall Square Association, and Weizmann Institute's Bina accelerator.
Recognized for her visionary leadership and personal contributions to individuals and organizations, she recently won the prestigious inaugural Kendall Square Founders award.
Michal holds a Bachelor’s degree in Medicine from Hebrew University, Msc and Ph.D. degrees in Biological Sciences from the Weizmann Institute of Science and an MBA from INSEAD.

Dr. Michal Tsur is co-founder and co-CEO of Remepy, that is pioneering hybrid drugs. Prior to Remepy, Michal was Kaltura’s co-founder and president (Nasdaq: KLTR). Kaltura’s video experience cloud powers engaging experiences for hundreds of millions of viewers at home, at work and at school. Prior to Kaltura, Michal co-founded Cyota, provider of security and anti-fraud solutions for financial institutions (acquired by RSA Security (Nasdaq: RSAS)). Michal holds a doctoral degree from NYU and was a post-doctoral fellow at Yale’s Information Society Project. Michal loves to run, swim and hike, and regularly blogs and writes.

Michael Gladstone is a partner at Atlas Venture and focuses on building new therapeutics companies.
Michael is a co-founder and board member of Diagonal Therapeutics and Third Harmonic Bio (NASDAQ: THRD), and a board member of Day One Biopharmaceuticals (NASDAQ: DAWN), Kailera Therapeutics, Pheon Therapeutics, and several stealth NewCos. Michael was previously a board director for Aiolos Bio (acquired by GSK) and Versanis Bio (acquired by Lilly).
Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on HIV vaccines with Harvard Medical School Professor Norman Letvin.
Michael received an AB in biochemical sciences with highest honors from Harvard College.

Natalie Artzi is a distinguished biomedical scientist-engineer renowned for her transformative
contributions to structural nanomedicine. Her pioneering work on tissue- and cell-responsive
materials has significantly advanced the field of biomedical engineering. Artzi has developed materials that activate based on chemical cues, enabling targeted drug delivery and creating a novel "depot effect" where nanotherapeutics are released to neighboring cells to enhance immune therapy. She currently directs the Center for Structural Nanomedicine at the Gene and Cell Therapy Institute at Harvard Medical School and leads a $27 million ARPA-H grant, the first at Harvard University.

Nitsan is the Senior Director of Innovation and Growth at the Ministry of Economy and Industry and has held various roles in the public sector for the past ten years.
Nitsan has played pivotal roles, from Chief of Staff to the Director General of Economy and Energy. With a keen ability to bridge the gap between political agendas and professional
implementation, she is entrusted with translating ministerial directives into actionable strategies. Her extensive experience in team leadership, complex project management, and
leadership development is a testament to her ability to manage strategic projects, including negotiations on maritime borders with Lebanon.
She holds an M.A. in Public Policy and a B.A.in Economics and Political Science.
Nitsan, lives in Jerusalem with her husband, Netanel, and their two sons, Sahar and Amir.

Noam Shomron is passionate about using basic science to advance better healthcare. He is a Professor of Digital Medicine and Functional Genomics at the Faculty of Medical & Health Sciences at Tel Aviv University after training at MIT. He leads a multidisciplinary team of scientists that develops computational methods for parsing big data in the bio-medical field using Artificial Intelligence. Noam published hundreds of peer-reviewed publications on multiple genomic fields; Editor of ‘Deep Sequencing Data Analysis’ book (Springer, Edition I 2013, and II 2021); Director of Djerassi Institute of Oncology; Academic Director of ‘ScienceAbroad’ (NPO); ranked Major in the army forensic lab; Co-founder of several Biotech and Digital Medicine companies: Variantyx, GotSho, IdentifAI, Everly Bio, 4nZOK, among others.

Oded Rose served as CEO of the Israel-America Chamber of Commerce until January 2025 and is now a Senior Advisor for U.S.-IL Healthcare collaboration.
At AmCham, Oded has led a program funded by the U.S. Congress, to promote U.S.-Israel HealthTech collaboration. The program facilitated market immersion for nearly 40 leading Israeli HealthTech startups in New England. Additionally, Oded developed a reciprocal initiative with the Israeli Ministry of Health and Israeli hospitals to encourage U.S. companies to bring their technologies to Israel.
Before that, Oded was the CEO of Flow Industries, a startup in the water and energy sectors. He previously was VP of Marketing and Sales at Pollogen, a medical device company, and at Atlantium, a leader in industrial and municipal water disinfection.
Earlier, Oded was the Founder of Aurum Ventures, where he served on the boards of over 20 companies in medical equipment, biotech, telecom, and software.
Oded holds a Master of Science in Medical Research from Tel Aviv University, an MBA and an MA in International Studies from the Wharton School of Business at the University of Pennsylvania.
He is the founder of EMIS, an international high school dedicated to promoting peace and sustainability through education. The school has Israeli students, as well as Palestinians, Arabs, and other nationalities.

Phyllis Gotlib leads Amwell's international operations. Before joining Amwell. Phyllis was an Executive Partner at Flare Capital. She also served as co-founder and CEO of iMDsoft, a disruptive clinical information technology company that created innovative, market-leading solutions to streamline and optimize hospitals' high-acuity care. Phyllis led iMDsoft from inception through its exponential international growth and ultimately to its acquisition by TPG Growth in 2012. Before iMDsoft, she founded PS Gluck, a lucrative diamond trade company that she managed for many years with her partner in the Israeli Diamond Exchange (IDE). After she departed from PS Gluck, Phyllis joined Tactic Capital Markets (TCM), a boutique investment firm, as a managing partner. At TCM, Phyllis began to focus on healthcare investments. In addition to her business ventures, Phyllis is an active philanthropist and social activist. She holds leadership roles in various not-for-profit organizations including Zahal Disabled Veterans Organization (ZDVO) and the Israel American Council (IAC). Phyllis works closely with Flare Capital's entrepreneurs, providing deep healthcare technology insights and experience to support portfolio companies in becoming market leaders.

Dr. Raanan Cohen is a leader and a strong change agent in the pharma space in Israel. An experienced manager, he has built many collaborations between hospitals, Sick-funds, MoH, the Israel Innovation Authority, together with international pharma.
Dr. Cohen serves as regional director at AbbVie Oncology Early Development . In the past served as clinical medical and commercial director in oncology in various big Pharma. Was responsible for scouting for MSD and Abbvie in Israel. Has strong "can do" mentality, has helped to improve the Israeli HealthTech ecosystem in several aspects, including: early phase Oncology research, RWE research, CT regulations and more.
Dr. Cohen is highly committed to be an Israeli ambassador, both internally in his company and externally, in order to eventually position Israel as a bio-pharma leader.

Prof. Ran Balicer is a physician, scientist and executive, Deputy-DG and Chief Innovation Officer for Clalit - Israel's largest healthcare organization caring for over half of Israel’s population. He is also the Founding Director of the Clalit Research Institute, the WHO Collaborating Center on Non-Communicable Diseases Research, Prevention and Control.
Prof Balicer is Full Professor and Track Director of the MPH program at the Ben-Gurion University School of Public Health, and heads Israel’s first and only Public Health/Data Sciences combined physician residency program. He also serves as Co-Chair of the Ivan and Francesca Berkowitz Family Living Collaboration Laboratory at Harvard Medical School & Clalit Research Institute.
Prof. Balicer also serves as an Advisor to the World Health Organization (WHO) focusing on utilizing data science and AI.
He had been serving as Chair of the Israeli Society for Quality in Healthcare since 2013, and as member of key international teams and boards - including the board of HIMSS, the Commission of the Lancet and Financial Times on Digital Health Futures, the French Government 3IA/AI cluster International Advisory Board, and as a Member of the UN Secretary-General Recently formed global Advisory Board on AI.

Ran has been the Deputy Director General and Head of the Economics, Regulation and Innovation Directorate of the Israeli Ministry of Health since
October 2021. As one of the key senior managers in the health system, he’s in charge of the Ministry’s regulation and supervision of the HMOs, The Digital
Health and IT divisions and oversees the Ministry's regulation of the various economic sectors under its jurisdiction. His Directorate consists of five different
divisions with a total annual operating budget of more than $100M and over 450 staff.
Previously, Ran was the Board Member of Israel to the OECD in Paris and served as head of the Healthcare team and the Head of the Labor Market team in the Budget Department at the Ministry of Finance. He also served as a board member in "Ashra" and was a member of the Israeli Health Services Basket Committee for 4 years.
Ran holds a master's degree in financial economics and a BA summa cum laude in PPE, both from the Hebrew University of Jerusalem.

Rani Dudai is an experienced executive with over 25 years of leadership experience, currently serving as the CEO of JDC-TEVET, a key initiative between the Government of Israel and JDC Israel, focused on innovating and improving quality employment integration in the Israeli economy. His role involves spearheading strategic partnerships that promote human capital development and increase productivity. Additionally, Rani holds influential positions as a board member at the Ruppin Academic Center, and founder and committee chairman of the Yossi Bachar Fellowship. He is also actively involved in JDC Israel, where he contributes to the development of social services and cross-sector partnerships aimed at improving the quality of life for Israel's most vulnerable populations. A graduate of Haifa University with an MBA in Strategic Human Resource Management, Rani is further recognized as a Harvard Business School alumnus through the High Potential Leadership program and is a proud member of the 8400 Health Network. His commitment to societal improvement is complemented by his military service as a captain in the Israel Air Force, underscoring his robust leadership capabilities across diverse and challenging environments.

Mr. Brudnick is the Chief Business Officer at Prime Medicine. Prior to joining Prime Medicine, he was Chief Business Officer for Codiak BioSciences, an exosome therapeutics company. Before Codiak, Mr. Brudnick was EVP of Business Development at Bioverativ, Inc., a company he helped found and which was later acquired by Sanofi for $11.6 billion. Mr. Brudnick joined Bioverativ at its spin-off from Biogen where, over the course of nearly 15 years, he initiated, led and completed transactions that led to several marketed products. Mr. Brudnick also was CEO of a regional pharmaceutical distribution business, which he sold to a strategic buyer; co-founded two companies; and was a strategy consultant at Bain & Company. Mr. Brudnick holds degrees from MIT and the Sloan School of Management and serves as a director of Scholar Rock and InflaRx.

Ronit Satchi-Fainaro is a full Professor at Tel Aviv University, where she is head of the Cancer Research & Nanomedicine Laboratory, Director of the Cancer Biology Research Center, and Director of the TAU Kahn 3D BioPrinting Initiative. She received her B.Pharm. from the Hebrew University in Jerusalem and her Ph.D. from UCL, followed by a Postdoctoral Fellowship at Harvard University and Children’s Hospital Boston. She has authored over 160 publications, 13 book chapters, edited 2 books, is named inventor on 95 patents, some of which were licensed to Pharmaceutical and Biotech companies, founded 3 spin-off companies, initiated 2 clinical trials, and has delivered over 650 plenary presentations and invited lectures worldwide. Her students are pursuing careers in academia, industry, hospitals, and government. She is actively engaged in translational research with several industry partners and in science outreach. She serves on the BoD of Teva Pharmaceutical Industries, is a member of the SAB of the Blavatnik Center for Drug Discovery, Israel Cancer Association, University of Lisbon, VHIR, VCs, and editorial boards of scientific journals.

Sam is a Venture Partner at aMoon Fund. He is a recently retired executive from Bristol Myers Squibb, a global biopharma company. In his most recent capacity as Head of Corporate Strategy, Sam led the strategic direction of the company with close linkage to all of its major businesses, functions and geographies. Among core priorities was the development/implementation of corporate digital strategy and the $90B acquisition/integration of Celgene.
Prior to this role, Sam was President of several global businesses at BMS.
Today Sam serves in Board and advisory roles, focused on the growth and global expansion of Israeli HealthTech innovation. He is also active in the educational non-profit sector in the US and Israel.

Shira is a Partner at Vintage Investment Partners where she leads the firm's investments in Healthcare and Climate. Prior to joining Vintage, Shira managed an NGO for non-formal education. Before that, Shira worked as a Strategic Consultant for McKinsey & Company. Shira was also a ‘Milken’ fellow in the Ministry of Economy, focusing on the export of Israel’s water technologies. Shira holds a BSc in Math and Computer Science from Ben Gurion University and an MSc in Environmental Change and Management from Oxford University.

Shiri is a Senior Director with Teva Pharmaceuticals' Global Business Development group, heading all the Neuroscience Search and Evaluation and Transaction global activities, and led several other licensing and divestment transactions over the past few years. Before joining Teva, Shiri was working with a few consulting and Biotech firms, always targeting the intersection of science, business and cultural difference. Shiri holds a B.Sc. in Biotechnology Engineering from Ben-Gurion University, M.Sc. in Medical Science from the Tel Aviv University, and MBA from the Reichman University .

Professor Shulamit Levenberg is the head of the Stem cell and Tissue engineering lab at the Technion Faculty of Biomedical Engineering and the Center for 3D Bioprinting's director.
She earned her PhD at the Weizmann Institute of Science and pursued her post-doctoral research at MIT in Professor Robert Langer's lab. She spent a year as a visiting professor at the Wyss Institute for Biology Inspired Engineering at Harvard University and a summer sabbatical at the University of Western Australia.
Her research involves in-vitro vascularization of engineered tissues. She has won numerous prizes, including the Rappaport Prize for Excellence in Biomedical Sciences, the Michael Bruno Memorial Award, the Katz prize and a Medal of Distinction from the Peres Center for Peace and Innovation.
She is the founder and CSA of three start-up companies in the areas of cultured meat, spinal cord regeneration and nanoliter diagnostic arrays. She is the former President of the Israel Stem Cell Society, former Dean of the Technion Faculty of Biomedical Engineering and former member of the Israel National Council for Bioethics. She is a member of the American Institute for Medical and Biological Engineering and National Academy of Inventors.

Tomer joined Harel in 2021 to lead the technology investment practice focused on partnering with early-stage companies across Life Sciences, Health Care, FinTech and Enterprise IT. Before that, Tomer was part of Cisco Investments, leading acquisitions and investments in Israel. Prior to that, Tomer was a Senior Product Manager at Audible and a Management Consultant.
He holds an MBA from Columbia University and an LLB from the University of Haifa.

A managing partner at Team8. A practicing family physician. I have done my post doc in medical informatics at Johns Hopkins. Founded and managed the medical informatics department in Maccabi. Head of primary care division in Maccabi and then founder and CEO of KSM the research and innovation center in Maccabi. A full professor of epidemiology in Tel Aviv University.
A director at Teva.

Since 2024, Yael serves as VP & Head of Policy division in Israel Innovation Authority, leading policy reforms, structuring IIA's strategy & tools and conducting economical research as well as managing the IIA's budget. Before that, Yael served as VP Operations in Ukko, a biotech company revolutionizing the treatment of food allergies, where she lead project and program management as well as clinical operations. Prior to that, Yael worked in government in different roles: CFO and Deputy Head of Digital Israel, where she was in charge of leading Digital Transformation in Government, in areas such as Health, Finances, Law Enforcement etc; Chief of Staff to the Director General of Labor Division, in charge of leading reforms and strategy in areas such as Vocational Training, Workforce Inclusion, Future of Work and more; Advisor at the Director General of the Ministry of Finance.
Yael is an alumna of the Civil Service Cadet Program excellence program, of the Maoz Leaders network and she is a captain in the reserves, after serving in the IDF's 8200 unit for five years. She has a Master in Public Policy, and Bachelor of Laws (LL.B.) and Economy (B.A).

Dr. Yair Schindel is the Co-Founder & Managing Partner of aMoon.
Before launching aMoon Yair served as the founding CEO of Digital Israel, the State’s National Digital Bureau established within the Israeli Prime Minister’s Office.
Prior to that, Yair was the CEO of Startup Nation Central, a nonprofit organization that connects major international businesses, governments, and NGO’s to Israeli innovation.
Yair was co-founder, and later a board member, of MAOZ, an NGO that trains and connects Israel’s most promising future leaders to promote social change initiatives.
Yair served as an executive, investor, board member, or advisory board member in several healthcare startups, including OmniGuide, MDClone, Medisafe, Zebra, Adicet, Cartiheal, Igentify, and DayTwo.
Yair is the co-founder and chairman of 8400 – The Health Network, which is building a coalition of public, private, and nonprofit sector leaders to build a national HealthTech growth engine.
Yair earned his BSc and MD degrees at Ben-Gurion University and his MBA at the Harvard Business School. He currently serves on the Health Care Advisory Board at HBS. Yair served for five years as a physician with IDF Special Forces. In his last position, Yair was the Chief Medical Officer for the Israeli Navy Seals.

Yifat completed her PhD and postdoctoral studies at Harvard Medical School and is now an Associate Professor at the Weizmann Institute of Science. Her interdisciplinary group combines basic and translational research to develop the field of epiProteomics, revealing mechanisms of post-translational modification and protein degradation, focusing on cancer and immune regulation. With her platform technologies, she enables novel approaches for drug discovery and therapeutic interventions.
She is the recipient of numerous academic and industry fellowships and awards, including the 2023 Scientific Council Prize at Weizmann and the 2024 Rappaport Prize for excellence in biomedical research.
She is a scientific Co-Founder of two biotech companies and a co-inventor of several patent applications.

Dr. Yuval Cabilly is Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Cabilly has vast experience in identifying, funding and engaging in business development activities of Israeli biotech companies.
He received his PhD in molecular cell biology from Tel Aviv University, where he focused his research on neurodegenerative disease. Several of his articles have been published in well-known scientific journals.

Mr. Gradus currently serves as the head of the Budget Department at the Israeli Ministry of Finance. Prior to his current role, he was the deputy head of the department. He managed four teams that cover Macro-Fiscal policy; Public sector wages and HR, Pension policy; Financial sector policy; Prices supervision committee; Economic research and Budget IT.
Prior to that, he was the head of the team at the Ministry of Finance that is in charge of the Welfare, National Insurance and immigration budgets and economic policies. Prior to this, he graduated from the Harvard Kennedy School with a Master in Public Administration where he was a Wexner Israel Fellow. Before studying at Harvard, he served as the Head of The State Budget Team in the MOF Budget Department. Among other things Yogev's team was responsible for constructing the macro-fiscal strategy of the government and for the managing the state budget process. In addition, Yogev was also in charge of the Israeli Culture and Sports Budgets and he was a member of the Board of Directors and the Head of the Finance Committee of Port of Haifa Company.
Before joining the Budget Department, he served in a few of the ministry's departments and was the Parliamentary Assistant to Knesset Member Roni Bar-On.
Besides his MPA from Harvard Yogev holds a Master of Business Administration and Bachelor of Arts in Economics and Accounting (summa cum laude) both from the Hebrew University of Jerusalem. He is living happily in Kfar-Sava with Bella, a Doctor of Veterinary Medicine, and their two daughters and son Gal, Amit and Alon.